Imvax achieves survival boost in glioblastoma with IGV-001

Imvax, a biotech based in Philadelphia, announced top-line results from a randomized, multicenter Phase 2b trial for IGV-001 in patients with newly diagnosed glioblastoma (GBM), showing a significant overall survival (OS) benefit compared with placebo and a favorable safety profile. IGV-001 is an autologous biologic-device combination product candidate that involves implanting biodiffusion chambers directly into the tumor in order to deliver personalized whole tumor-derived cells with an antisense oligonucleotide.

In the study of 99 patients (2:1 randomization), those receiving IGV-001 achieved a median OS of 20.3 months versus 14.0 months in the placebo arm, representing a +6.3 months (45%) survival gain over standard-of-care alone. Median follow-up was 22 months.

Importantly, no drug-related serious adverse events were reported in the IGV-001 arm, and the safety profile remained consistent with prior Phase 1b data.

Despite the survival benefit, the trial did not meet its primary endpoint of improved progression-free survival (PFS).

The GBM challenge

GBM is an aggressive and lethal primary brain tumor that represents a major challenge in neuro-oncology. The disease is characterized by rapid growth, resistance to conventional therapies, and poor prognosis. Understanding of the disease biology continues to evolve, with recent focus on tumor differentiation and gene expression profile highlighting the complexity and heterogeneity of GBM. The standard of care remains restricted to surgical resection, radiotherapy, and concurrent and adjuvant chemotherapy with temozolomide.

Given the aggressive nature of GBM and lack of major advances in first-line therapy over decades, the survival improvement achieved by IGV-001 is clinically meaningful. Imvax said it plans to approach the US FDA soon to discuss a development path based on the positive risk-benefit profile.

According to Imvax, IGV-001 uses the company’s proprietary Goldspire Platform, an autologous, whole-tumor–derived immunotherapy combined with a biologic/device approach. Following surgical resection of the tumor, patients receive biodiffusion-chamber implants containing processed, patient-derived tumor material plus an antisense oligonucleotide. The chambers are removed after a short dwell time, and standard adjuvant therapy (radiotherapy + temozolomide) proceeds as usual.

In remarks, Imvax’s executive chair described the results as a “potential watershed moment” for GBM therapy, noting the large unmet need and the opportunity to integrate IGV-001 into the standard-of-care paradigm if regulatory engagement proves successful.

Other companies with active pipelines for GBM include: Inovio Pharmaceuticals, Pfizer, Roche, AbbVie, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Mustang Bio, Bullfrog AI Holdings, Cantex Pharmaceuticals.